In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will receive treatment right up until disease progression or the contributors are unable to tolerate the study drugs. Doable new strategies to the analysis and treatment of AML. (A) The https://vonu110kwg3.wikilinksnews.com/user